Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia (NCT07441876)

🧪 Interventions in This Study

• BMN 333 (DRUG)
• Vosoritide Injection [Voxzogo] (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (25 Sites)

• UCSF Benioff Children's Hospital Oakland — Oakland, California
• Nemours Children's Health — Wilmington, Delaware
• Ann & Robert H. Lurie Children's Hospital of Chicago — Chicago, Illinois
• Johns Hopkins Medicine — Baltimore, Maryland
• Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio
• Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
• University of Texas Southwestern Medical Center — Dallas, Texas
• Texas Children Hospital, Baylor College of Medicine — Houston, Texas
• Consano Clinical Research, LLC — San Antonio, Texas
• Murdoch Children's Research Institute — Parkville, Victoria
• Universite de Montreal - Centre Hospitalier Universitaire Sainte-Justine — Montreal, Quebec
• Irccs Ospedale Gaslini Di Genova — Genova,
• Hokkaido University Hospital — Hokkaido,
• Osaka City General Hospital — Osaka,
• National Center for Child Health and Development — Tokyo,
• Uniwersytecki Szpital Kliniczny im. J. Mikulicza-Radeckiego we Wroclawiu Klinika Pediatrii i Chorob Infekcyjnych — Wroclaw,
• Institutul National de Endocrinologie C.I.Parhon — Bucharest,
• Craiova Emergency Clinical County — Craiova,
• Seoul National University Hospital — Seoul,
• Pusan National University Yangsan Hospital — Yangsan,
• University Hospitals Bristol NHS Foundation Trust - Bristol Royal Hospital for Children — Bristol,
• Queen Elizabeth University Hospital — Glasgow,
• Alder Hey Childrens NHS Foundation Trust — Liverpool,
• Great Ormond Street Hospital — London,
• University NHS Foundation Trust NIHR Wellcome Trust Clinical Research Facility — Manchester,

📞 Contact the Study Coordinator

Phone: (800) 983-4587

Email: medinfo@bmrn.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Achondroplasia

• A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH) — Oakland, California
• An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia — Oakland, California
• An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia — Oakland, California
• Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH) — Oakland, California
• A Study of TYRA-300 in Children With Achondroplasia: BEACH301 — Torrance, California
• VIrtual STudy in Achondroplasia for the US (VISTA) — Oakland, California

Explore by condition: All Achondroplasia clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.